Exonics Therapeutics Stock

exonicstx.comHealthcare / BioTech & PharmaFounded: 2017Funding to Date: $45MM

Developer of gene repair therapies designed for devastating genetic neuromuscular diseases. The company's uses CRISPR/Cas9 technology which is a potential one-time treatment that would make a permanent correction of the mutation that causes Duchenne by identifying and correcting exon mutations that prevent the production of dystrophin, a protein that helps stabilize and protect muscle fibers, enabling patients to improve their lives and have a lifelong benefit.

Register To Buy and Sell Shares

For more details on financing and valuation for Exonics Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Exonics Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Exonics Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

John Ripple
Chief Executive Officer & Board Member
David Goeddel Ph.D
Chairman
Jesper Gromada Ph.D
Chief Scientific Officer
Eric Olson Ph.D
Founder, Chief Science Advisor & Board Observer

Board Members

John Edwards
Eric Olson Ph.D
David Goeddel Ph.D
JeenJoo Kang Ph.D
The Column Group
John Ripple

Frequently Asked Questions About Exonics Therapeutics’ Stock

plusminus
Can you buy Exonics Therapeutics’ stock?
Exonics Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Exonics Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Exonics Therapeutics’ stock?
Yes, you can sell stock of a private company like Exonics Therapeutics. Forge can help you sell your Exonics Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Exonics Therapeutics’ stock price?
Exonics Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Exonics Therapeutics’ private market stock price with Forge Data.
plusminus
What is Exonics Therapeutics’ stock ticker symbol?
Exonics Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Exonics Therapeutics Secures $40M in Series A Financing |FinSMEs
Exonics Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company, secured $40m in Series A financing. The Column Group (TCG), a science-driven venture capital firm, made the investment. In conjunction with the funding, TCG’s David Goeddel, Ph.D., managing partner, and JJ Kang, Ph.D., principal, will be joining the company’s board of directors. The company intends to use …
Updated on: May 23, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.